Evidence map›Paper›PMID 35723389›Full record

ArticleCurrent issues in molecular biology2021

Familial Hyperaldosteronism Type 3 with a Rapidly Growing Adrenal Tumor: An In Situ Aldosterone Imaging Study.

Nae Takizawa, Susumu Tanaka, Koshiro Nishimoto, Yuki Sugiura, Makoto Suematsu, Chisato Ohe, Haruyuki Ohsugi, Yosuke Mizuno, Kuniaki Mukai, Tsugio Seki and 3 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Current issues in molecular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. 18-Oxocortisol: A journey.The Journal of steroid biochemistry and molecular biology · 2023
    Article
  4. Molecules at Play in Cancer.Current issues in molecular biology · 2023
    Article
  5. Primary aldosteronism caused by a pI157S somaticFrontiers in endocrinology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Nae TakizawaDepartment of Urology and Andrology, Kansai Medical University, Osaka 573-1191, Japan.ORCID 0000-0001-6469-7546
Susumu TanakaDepartment of Anatomy, Kansai Medical University, Osaka 573-1191, Japan.ORCID 0000-0003-4804-7839
Koshiro NishimotoDepartment of Uro-Oncology, Saitama Medical University, International Medical Center 1397-1 Yamane, Hidaka 350-1298, Japan.
Yuki SugiuraDepartments of Biochemistry, School of Medicine, Keio University, Tokyo 160-8582, Japan.
Makoto SuematsuDepartments of Biochemistry, School of Medicine, Keio University, Tokyo 160-8582, Japan.
Chisato OheDepartment of Pathology, Kansai Medical University, Osaka 573-1191, Japan.
Haruyuki OhsugiDepartment of Urology and Andrology, Kansai Medical University, Osaka 573-1191, Japan.
Yosuke MizunoBiomedical Research Center, Division of Morphological Science, Saitama Medical University, Saitama 350-0495, Japan.
Kuniaki MukaiDepartments of Biochemistry, School of Medicine, Keio University, Tokyo 160-8582, Japan.ORCID 0000-0002-9590-5077
Tsugio SekiDepartment of Medical Education, California University of Science and Medicine, Colton, CA 92324, USA.
Kenji OkiDepartment of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.ORCID 0000-0002-9225-8193
Celso E Gomez-SanchezMedical Service, G.V. (Sonny) Montgomery VA Medical Center, Department of Pharmacology and Toxicology, Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Tadashi MatsudaDepartment of Urology and Andrology, Kansai Medical University, Osaka 573-1191, Japan.
Kansai Medical University · JPKeio University · JPSaitama Medical University · JPHiroshima University · JPUniversity of Mississippi Medical Center · US

Funding

Tracking and Evaluation CoreU54GM115428 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI MASON, SARAH · 2016 to 2025
$38.2M
Adrenal cell ATP1A1 mutations and mechanisms of aldosterone biosynthesisR01HL144847 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI GOMEZ-SANCHEZ, CELSO ENRIQUE · 2019 to 2022
$1.3M
BLRD VA I01 BX004681NHLBI NIH HHS R01 HL144847NIGMS NIH HHS U54 GM115428
6 · The paper itself

Abstract

Primary aldosteronism is most often caused by aldosterone-producing adenoma (APA) and bi-lateral adrenal hyperplasia. Most APAs are caused by somatic mutations of various ion channels and pumps, the most common being the inward-rectifying potassium channel

Indexed as

adrenal tumorCYP11B2familial hyperaldosteronism type 3KCNJ5MALDI-IMSβ-catenin

Identifiers

PMID35723389
PMCPMC8929039
OpenAlexW4200174848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.